As such, we next assessed the regulatory activities of our DC10 in our mouse model of OVA-induced asthma, treating asthmatic mice with OVA-pulsed w.t. or CD40-/- DC10 and assessing their asthma phenotype 4 wk later (Fig 2), when the regulatory effects of DC10 have achieved essentially full penetrance, as reported previously [5, 19]. The gene discussed is FBXO8; the disease is asthma.